Follow
Cancer Therapeutics
Cancer Therapeutics: Cancer is often treated by surgery, chemotherapy, radiation therapy, targeted therapy (including immunotherapy such as monoclonal antibody therapy), hormonal therapy, and synthetic lethality. The choice of therapy depends upon the stage of the disease, and the location and grade of the tumor, as well as the patient's general status. Many clinical trial cancer treatments are also under development.
OCT 30, 2014 | 3:00 PM
Oncogenic mutations in isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2) compromise their normal activity and induce NADPH-dependent (D)2-hydroxyglutarate (2HG) production within the cytosol or m...
OCT 30, 2014 | 12:00 PM
Female cancer patients in the reproductive years face a variety of diagnostic and therapeutic procedures which pose teratogenic hazards to an unexpected pregnancy. Ionizing radiation, diagnos...
OCT 30, 2014 | 12:00 PM
Although the incidence of breast cancer is steadily increasing, mortality rates are decreasing. This means that the majority of women with breast cancer now survive, making it even more impor...
OCT 30, 2014 | 10:30 AM
The era of omics has ushered in the hope for personalized medicine. Proteomic and genomic strategies that allow unbiased identification of genes and proteins and their post-transcriptional a...
OCT 30, 2014 | 10:30 AM
Many drugs currently used for anti-cancer therapy demonstrate significant inter-individual variability that cannot be normalized using body weight or body surface area. There is an increasing...
OCT 30, 2014 | 6:00 AM
When the BCR/ABL1 fusion protein was identified in chronic myelogenous leukemia and the JAK2 V617F mutation was identified in patients with other myeloproliferative neoplasms (MPNs) such as p...
OCT 29, 2014 | 3:00 PM
Over the last decade we have witnessed tremendous advances in our understanding of the underlying molecular alterations in human cancer. This has stimulated excitement for our ability to deve...
OCT 29, 2014 | 1:30 PM
Human malignant glioma is a uniformly fatal disease, causing over 14,000 deaths in the US this year. Adults diagnosed with malignant brain tumors have a median survival of approximately 15 mo...
OCT 29, 2014 | 9:00 AM
Post-translational methylations play central roles in epigenetic gene regulation pathways that are central to stem cell regulation. Lysine methylations are turn-on switches for hundreds of di...
OCT 29, 2014 | 9:00 AM
Although robust and clinically meaningful biomarkers are key to achieving the current vision for precision (molecularly based), cancer medicine (patient stratification, early diagnosis, drug...
OCT 29, 2014 | 7:30 AM
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision-making. An...
SEP 16, 2014 | 10:00 AM
Patients with chromosomal rearrangements resulting in fusion proteins are among the most responsive to published targeted therapy. For example, targeting of the EML4-ALK fusion in non-small c...
SEP 16, 2014 | 9:30 AM
Late-stage drug attrition rates in oncology remain higher than in other therapeutic areas. To reduce attrition, it is critical to identify appropriate drug targets and pre-clinical models. Th...
AUG 20, 2014 | 10:45 AM
A recent publication in Nature Genetics1 analyzed TCGA data, and classified solid tumors into two mutually exclusive classes: C class tumors, driven by copy number alterations; and M class tu...
MAY 29, 2014 | 12:00 PM
Pharmcogenomics (PGx) is the 2nd potential clinical application of genomic medicine, preceded by genomic application for cancer. In the recently published, 2012 Institute of Medicine report o...
